Acute and long-term (2-years) clinical outcomes of the CoreValve 31mm in large aortic annuli: A multicenter study

GF Attizzani, Y Ohno, A Latib, AS Petronio, C Giannini, F Ettori, S Curello, F Bedogni, D Todaro, N Brambilla, G Bruschi, P Colombo, P Presbitero, R Fiorilli, A Poli, P Martina, A Colombo, M Barbanti, C Tamburino

Research output: Contribution to journalArticlepeer-review

Abstract

INTRODUCTION: Little is known about the early and late performance of the 31mm CoreValve Revalving System (CRS, Medtronic Inc., Galway, Ireland). Our aim was to compare acute and long-term results of the 31mm CRS with other valve sizes. METHODS: Consecutive patients undergoing transcatheter aortic valve implantation (TAVI) with CRS in nine Italian centers were prospectively included and dichotomized according to prosthesis size in two different groups, as follows: 31mm and other valve sizes (i.e., 23, 26, and 29mm combined). End points were defined according to Valve Academic Research Consortium definitions. Propensity score matching was performed. RESULTS: In total, 2069 patients (n=169 [8%] in the 31mm group and n=1900 [92%] in the other valve sizes group) were included. After propensity matching, the implantation of the 31mm valve was associated with lower rates of procedural- (91.3% vs. 98.1%, p=0.030) and device-success (88.5% vs. 97.1%, p=0.016), longer procedural time (120 [80-180] min. vs. 90 [60-120] min., p
Original languageEnglish
Pages (from-to)543-549
Number of pages7
JournalInternational Journal of Cardiology
Volume227
Issue number13
DOIs
Publication statusPublished - 2017

Fingerprint Dive into the research topics of 'Acute and long-term (2-years) clinical outcomes of the CoreValve 31mm in large aortic annuli: A multicenter study'. Together they form a unique fingerprint.

Cite this